
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : EPY201
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : UCL Technology Fund
Deal Size : $10.0 million
Deal Type : Financing
EpilepsyGTx Raises $10 Million for CTA-Enabling Nonclinical Package for EPY201
Details : The funds raised will be used to complete the preclinical studies for EpilepsyGTx’ lead gene therapy program EPY201, for the treatment of focal refractory epilepsy.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
June 24, 2024
Lead Product(s) : EPY201
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : UCL Technology Fund
Deal Size : $10.0 million
Deal Type : Financing
